MedPath

THEOPHYLLINE

Theophylline Extended-Release Tablets

Approved
Approval ID

90cdb3d4-3f0b-4a29-9cdf-278f4f588ce1

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 17, 2023

Manufacturers
FDA

Rhodes Pharmaceuticals

DUNS: 831928986

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

THEOPHYLLINE ANHYDROUS

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code42858-700
Application NumberANDA214113
Product Classification
M
Marketing Category
C73584
G
Generic Name
THEOPHYLLINE ANHYDROUS
Product Specifications
Route of AdministrationORAL
Effective DateMay 17, 2023
FDA Product Classification

INGREDIENTS (6)

HYPROMELLOSE 2910 (15000 MPA.S)Inactive
Code: 288VBX44JC
Classification: IACT
THEOPHYLLINE ANHYDROUSActive
Quantity: 300 mg in 1 1
Code: 0I55128JYK
Classification: ACTIB
POVIDONE K30Inactive
Code: U725QWY32X
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.